Search

Search Constraints

You searched for: Author/Creator Rangan, V.

Search Results

1. CX-2043, an EpCAM-targeting probody drug conjugate, demonstrates anti-tumor activity with a favorable safety profile in preclinical models. (October 2020)

2. Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. Issue 7 (7th February 2018)